Technical Analysis for DFFN - Diffusion Pharmaceuticals Inc.

Grade Last Price % Change Price Change
grade B 4.4 -5.58% -0.26
DFFN closed down 5.58 percent on Friday, May 17, 2019, on 10 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical DFFN trend table...

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Gapped Down Weakness 0.00%
Narrow Range Bar Range Contraction -5.58%
NR7 Range Contraction -5.58%
Wide Bands Range Expansion -5.58%
Up 3 Days in a Row Strength -5.58%

Older signals for DFFN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. Its lead product candidate is transcrocetinate sodium, which is in Phase I/II clinical trials for re- oxygenating treatment-resistant tissue; and making the cancer cells more susceptible to the therapeutic effects of radiation therapy and chemotherapy. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily glioblastoma multiforme. In addition, it is developing RES-440, a soft anti-androgen compound for the treatment of acne vulgaris. The company is headquartered in Charlottesville, Virginia.
Medicine Biotechnology Cancer Oncology Chemotherapy Cancer Treatments Radiation Radiation Therapy Glioblastoma Macular Degeneration Brain Tumor Signal Transduction Glioblastoma Multiforme Acne Vulgaris Mtor Oncology Applications Protein Kinase B
Is DFFN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 11.0
52 Week Low 1.83
Average Volume 470,701
200-Day Moving Average 4.3165
50-Day Moving Average 4.085
20-Day Moving Average 3.955
10-Day Moving Average 4.443
Average True Range 0.5739
ADX 39.43
+DI 36.2119
-DI 16.6636
Chandelier Exit (Long, 3 ATRs ) 4.7683
Chandelier Exit (Short, 3 ATRs ) 4.4717
Upper Bollinger Band 5.6379
Lower Bollinger Band 2.2721
Percent B (%b) 0.63
BandWidth 85.102402
MACD Line 0.2226
MACD Signal Line 0.1736
MACD Histogram 0.049
Fundamentals Value
Market Cap 61.69 Million
Num Shares 14 Million
EPS -2.61
Price-to-Earnings (P/E) Ratio -1.69
Price-to-Sales 0.00
Price-to-Book 15.05
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.77
Resistance 3 (R3) 4.76 4.62 4.71
Resistance 2 (R2) 4.62 4.52 4.63 4.69
Resistance 1 (R1) 4.51 4.47 4.44 4.52 4.67
Pivot Point 4.37 4.37 4.34 4.38 4.37
Support 1 (S1) 4.26 4.28 4.19 4.28 4.13
Support 2 (S2) 4.12 4.22 4.13 4.11
Support 3 (S3) 4.01 4.12 4.09
Support 4 (S4) 4.03